Table 2 Response to asciminib subanalysis regarding baseline response.

From: Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

 

Resistant (9)

Intolerant (19*)

Total (29*)

Best response to asciminib

 All patients

  CHRa

9/9 (100%)

19/19 (100%)

29/29 (100%)

  CCyRa

3/9 (33%)

16/19 (84%)

19/29 (66%)

  MMRa

1/9 (11%)

11/19 (58%)

12/29 (41%)

  MR4.5a

0/9 (0%)

4/19 (21%)

4/29 (14%)

 Patients without response at baseline

  CCyRb

3/9 (33%)

5/8 (63%)

8/17 (47%)

  MMRb

1/9 (11%)

7/15 (47%)

8/24 (33%)

  MR4.5b

0/3 (0%)

4/19 (21%)

4/29 (14%)

  1. *Due to short follow-up, 2 patients were excluded from response analysis.
  2. CHR complete hematological response, CCyR complete cytogenetic response, MMR major molecular response, MR4.5 detectable disease with BCR-ABL1IS < 0.0032%.
  3. aPatients with CHR, CCyR, MMR, or MR4.5 at baseline were evaluable for hematologic, cytogenetic, or molecular response and were considered responders if they maintained their response. bEvaluable patients without a CCyR, MMR, or MR4.5 at baseline.
Back to article page